지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.9
- 수록면
- 590 - 604 (15page)
- DOI
- https://doi.org/10.22246/jikm.2021.42.4.590
이용수
초록· 키워드
오류제보하기
Objectives: The purpose of this study is to examine the safety of Korean medicine treatment in patients vaccinated with the AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19/AZD1222).
Methods: We investigated patients at Kyung Hee University Korean Medicine Hospital who were vaccinated with the AstraZeneca COVID-19 vaccine between June 1, 2021 and June 30, 2021. The safety of Korean medicine treatment was evaluated by examining adverse events that occurred within seven days of vaccination, including liver function and kidney function testing, assessment of the severity of adverse events, and examination of causality to vaccines and Korean medicine treatment.
Results: Eleven patients vaccinated with the first dose of the AstraZeneca COVID-19 vaccine were included. A total of 19 adverse events were reported: 15 systemic adverse events, three local adverse events, and one alanine aminotransferase increase. The most commonly reported systemic adverse events were fatigue (4 cases, 36.4%), headache (4 cases, 36.4%), and myalgia (4 cases, 36.4%). All adverse events were rated below moderate (grade 2) in severity. Systemic and local adverse events were evaluated as definitely related to vaccination and unlikely to be related to Korean medicine treatment, while alanine aminotransferase increase was evaluated as unlikely to be related to either the vaccine or Korean medicine treatment. Aspartate transaminase, Blood urea nitrogen, and creatinine were measured within the reference range after vaccination.
Conclusion: Our results suggest that the severity and frequency of adverse events in patients vaccinated with the AstraZeneca COVID-19 vaccine did not increase after Korean medicine treatment.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Connors M / 2021 / SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn / Ann Intern Med 174(5):687~690
World Health Organization / Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19vaccine AZD1222 Vaxzevria™, SII COVISHIELDTM)
Voysey M / 2021 / Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK / The Lancet 397(10269):99~111
Voysey M / 2021 / Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)vaccine: a pooled analysis of four randomised trials / The Lancet 397(10277):881~891
Folegatti PM / 2020 / Safety and immunogenicity of the ChAdOx1 nCoV-19vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial / The Lancet 396(10249):467~478
World Health Organization / Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19vaccine AZD1222 Vaxzevria™, SII COVISHIELDTM)
Voysey M / 2021 / Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK / The Lancet 397(10269):99~111
Voysey M / 2021 / Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222)vaccine: a pooled analysis of four randomised trials / The Lancet 397(10277):881~891
Folegatti PM / 2020 / Safety and immunogenicity of the ChAdOx1 nCoV-19vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial / The Lancet 396(10249):467~478
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Immunoglobulin A Vasculitis Following ChadOx1 nCoV-19/ AZD1222 (AstraZeneca COVID-19 Vaccine) Vaccination
Annals of Dermatology
2023 .05
-
Survey of Adverse Events After The First Dose of The ChAdOx1 nCoV-19 Vaccine: A Single-Center Experience in Korea
Infection and Chemotherapy
2021 .09
-
항공종사자와 코로나바이러스감염증-19 백신 예방 접종
항공우주의학회지
2021 .04
-
일개 한의과대학 재학생의 COVID-19 백신 접종에 대한 인식 조사
대한예방한의학회지
2021 .12
-
코로나-19 백신 예방접종 후 이상반응으로 중증응급진료센터를 내원한 환자분석: 다기관 후향적 관찰연구
대한응급의학회지
2024 .02
-
Adverse events and preventive measures related to COVID-19 vaccines
Clinical and Experimental Emergency Medicine
2021 .09
-
COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021
Osong Public Health and Research Persptectives
2021 .12
-
Review of COVID-19 Vaccines and Their Evidence in Older Adults
Annals of geriatric medicine and research
2021 .01
-
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
Osong Public Health and Research Persptectives
2021 .08
-
Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
Infection and Chemotherapy
2022 .03
-
Factors Associated with Adverse Events Following the First Dose of COVID-19 Immunization in Indonesia
성인간호학회지
2022 .06
-
Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience
Journal of Korean Medical Science
2021 .01
-
Adverse Events with the Pfizer-BioNTech COVID-19 Vaccine among Korean Healthcare Workers
Yonsei Medical Journal
2021 .12
-
Prevalence of Anti-PF4 Antibodies After First and Second ChAdOx1 nCoV-19 Vaccinations in Women With Adverse Events: A Brief Report and Literature Review
Annals of Laboratory Medicine
2023 .05
-
Effectiveness of BBV152 vaccine and ChAdOx1-S vaccine in preventing severe disease among vaccinated patients admitted to a designated COVID-19 hospital in India
Clinical and Experimental Vaccine Research
2024 .01
-
Stevens-Johnson Syndrome Following ChAdOx1 nCoV-19 Vaccination (AstraZeneca)
Annals of Dermatology
2023 .05
-
Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination
Journal of Korean Medical Science
2021 .08
-
Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study
Clinical and Experimental Vaccine Research
2021 .09
-
COVID-19 Vaccination in Korea
Infection and Chemotherapy
2023 .03
-
Challenges managing COVID vaccine-induced immune thrombotic thrombocytopenia in low-middle income countries
Clinical and Experimental Vaccine Research
2021 .09
이 논문의 저자 정보
최근 본 자료
댓글(0)
0